ITEM 7.A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

This information appears under “Quantitative and Qualitative Disclosures about Market Risk” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in Exhibit 99.1, which is incorporated herein by reference.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

These statements and data appear in Exhibit 99.1, which is incorporated herein by reference.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9.A. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s chief executive officer and chief financial officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this Report. Based on that evaluation, the chief executive officer and chief financial officer concluded that the Company’s disclosure controls and procedures, as of the end of the period covered by this Report, were effective such that the information required to be disclosed by the Company in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to management, including the chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding disclosure.

Management’s Report on Internal Control Over Financial Reporting

Management’s report on internal control over financial reporting is set forth in Exhibit 99.1, and is incorporated herein by reference. The Company’s independent registered public accounting firm, Ernst & Young, LLP, has audited the effectiveness of the Company’s internal control over financial reporting as of June 30, 2020. See “Report of Independent Registered Public Accounting Firm,” which appears in Exhibit 99.1.

Change in Internal Control Over Financial Reporting

No change in the Company’s internal control over financial reporting occurred during the fourth fiscal quarter of the fiscal year ended June 30, 2020, that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

ITEM 9.B. OTHER INFORMATION

Not applicable.

28

Table of Contents

 

 

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

See “Information about our Executive Officers” in Part I of this Report.

The Company has adopted a Code of Conduct that applies to its principal executive officer, principal financial officer and principal accounting officer, among others. The Code of Conduct is located on the Company’s website at TheCloroxCompany.com under Who We Are/Corporate Governance/Code of Conduct or https://www.thecloroxcompany.com/who-we-are/corporate-governance/codes-of-conduct/. The Company intends to satisfy the requirement under Item 5.05 of Form 8-K regarding disclosure of amendments to, or waivers from, provisions of its Code of Conduct by posting such information on the Company’s website. The Company’s website also contains its corporate governance guidelines and the charters of its principal board committees.

Information regarding the Company’s directors and corporate governance set forth in the Proxy Statement is incorporated herein by reference.

ITEM 11. EXECUTIVE COMPENSATION

Information regarding executive and director compensation, Management Development and Compensation Committee interlocks and insider participation and the report of the Management Development and Compensation Committee of the Company’s board of directors set forth in the Proxy Statement is incorporated herein by reference.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Information regarding security ownership of certain beneficial owners, management and directors and securities authorized for issuance under equity compensation plans set forth in the Proxy Statement is incorporated herein by reference.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

Information regarding certain relationships and related transactions and director independence set forth in the Proxy Statement is incorporated herein by reference.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

Information regarding principal accounting fees and services set forth in the Proxy Statement is incorporated herein by reference.

29

Table of Contents

 

 

PART IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a)

Financial Statements and Schedules:

        Consolidated Financial Statements and Reports of Independent Registered Public Accounting Firm included in Exhibit 99.1, incorporated herein by reference.

        Reports of Independent Registered Public Accounting Firm.

        Consolidated Statements of Earnings for the fiscal years ended June 30, 2020, 2019 and 2018.

        Consolidated Statements of Comprehensive Income for the fiscal years ended June 30, 2020, 2019 and 2018.

        Consolidated Balance Sheets as of June 30, 2020 and 2019.

        Consolidated Statements of Stockholders’ Equity for the fiscal years ended June 30, 2020, 2019 and 2018.

        Consolidated Statements of Cash Flows for the fiscal years ended June 30, 2020, 2019 and 2018.

        Notes to Consolidated Financial Statements.

(b)

Exhibits:

INDEX TO EXHIBITS

Incorporated by Reference

Exhibit

Number

Exhibit Description

Form

File No.

Exhibit

Filing Date

3.1

Restated Certificate of Incorporation.

10-K

001-07151

3.1

August 14, 2018

3.2

Bylaws (amended and restated).

8-K

001-07151

3.2

September 15, 2016

3.3

Certificate of Designations for The Clorox Company Series A Junior Participating Preferred Stock.

8-K

001-07151

3.1

July 19, 2011

4.1

Indenture, dated as of December 3, 2004, between the Company and The Bank of New York Trust Company N.A., as trustee.

8-K

001-07151

4.1

December 3, 2004

4.2

Indenture, dated as of October 9, 2007, between the Company and The Bank of New York Trust Company N.A., as trustee.

S-3ASR

333-200722

4.1

December 4, 2014

4.3

First Supplemental Indenture, dated as of November 9, 2009, among the Company, The Bank of New York Trust Company N.A., and Wells Fargo Bank, National Association, as trustee.

S-3ASR

333-200722

4.2

December 4, 2014

4.4

Second Supplemental Indenture, dated as of November 9, 2009, between the Company and Wells Fargo Bank, National Association, as trustee.

S-3ASR

333-200722

4.3

December 4, 2014

4.5

Third Supplemental Indenture, dated as of November 17, 2011, between the company and Wells Fargo Bank, National Association, as trustee.

S-3ASR

333-200722

4.4

December 4, 2014

4.6

Fourth Supplemental Indenture, dated as of September 13, 2012, between the Company and Wells Fargo Bank, National Association, as trustee.

S-3ASR

333-200722

4.5

December 4, 2014

4.7

Fifth Supplemental Indenture, dated as of December 9, 2014, between the Company and Wells Fargo Bank, National Association, as trustee.

8-K

001-07151

4.1

December 9, 2014

4.8

Sixth Supplemental Indenture, dated as of September 28, 2017, between the Company and Wells Fargo Bank, National Association, as trustee.

8-K

001-07151

4.1

September 28, 2017

4.9

Seventh Supplemental Indenture, dated as of May 9, 2018, between the Company and Wells Fargo Bank, National Association, as trustee.

8-K

001-07151

4.1

May 9, 2018

30

Table of Contents

 

 

Incorporated by Reference

Exhibit

Number

Exhibit Description

Form

File No.

Exhibit

Filing Date

4.1

0

Eighth Supplemental Indenture, dated as of May 8, 2020, between the Company and Wells Fargo Bank, National Association, as trustee.

8-K

001-07151

4.1

May 8, 2020

4.11

Description of Capital Stock of The Clorox Company

10-K

001-07151

4.10

August 14, 2019

10.1*

The Clorox Company Amended and Restated Independent Directors’ Deferred Compensation Plan, effective as of November 16, 2005, and amended and restated as of February 7, 2008.

10-Q

001-07151

10.55

May 2, 2008

10.2*

The Clorox Company Non-Qualified Deferred Compensation Plan, adopted as of January 1, 1996, and amended and restated as of July 20, 2004.

10-K

001-07151

10(x)

August 27, 2004

10.3*

Amendment No.1 to The Clorox Company Non-Qualified Deferred Compensation Plan.

10-K

001-07151

10.3

August 16, 2016

10.4*

The Clorox Company Annual Incentive Plan, amended and restated as of September 17, 2013.

10-K

001-07151

10.8

August 25, 2014

10.5*

The Clorox Company 2005 Stock Incentive Plan, amended and restated as of November 14, 2012.

10-Q

001-07151

10.1

February 5, 2013

10.

6

*

Form of Performance Share Award Agreement under the Company’s 2005 Stock Incentive Plan for awards made in 2017.

10-Q

001-07151

10.2

November 1, 2017

10.

7

*

Form of Performance Share Award Agreement under the Company’s 2005 Stock Incentive Plan for awards made in 2018.

10-Q

001-07151

10.2

October 31, 2018

10.8*

Form of Performance Share Award Agreement under the Company's 2005 Stock Incentive Plan for awards made in 2019.

10-Q

001-07151

10.1

October 31, 2019

10.9*

Form of Restricted Stock Unit Award Agreement under the Company’s 2005 Stock Incentive Plan.

10-Q

001-07151

10.1

October 31, 2018

10.10*

Form of Nonqualified Stock Option Award Agreement under the Company’s 2005 Stock Incentive Plan.

10-Q

001-07151

10.3

November 1, 2017

10.11*

The Clorox Company Amended and Restated 2005 Nonqualified Deferred Compensation Plan, effective January 1, 2008.

10-K

001-07151

10.18

August 19, 2008

10.12*

Amendment No. 1 to The Clorox Company Amended and Restated 2005 Nonqualified Deferred Compensation Plan.

10-K

001-07151

10.18

August 26, 2011

10.13*

Amendment No. 2 to The Clorox Company Amended and Restated 2005 Nonqualified Deferred Compensation Plan.

10-K

001-07151

10.13

August 16, 2016

10.14*

The Clorox Company Supplemental Executive Retirement Plan, as restated effective January 5, 2005, as revised August 13, 2009.

10-Q

001-07151

10.17

November 3, 2009

10.15*

Amendment No. 1 to The Clorox Company Supplemental Executive Retirement Plan, effective as of July 29, 2011.

10-Q

001-07151

10.21

November 3, 2011

10.16*

Amendment No. 2 to The Clorox Company Supplemental Executive Retirement Plan, effective as of September 11, 2012.

10-Q

001-07151

10.2

November 2, 2012

10.17*

Amendment No. 3 to The Clorox Company Supplemental Executive Retirement Plan, effective as of March 28, 2018.

10-Q

001-07151

10.1

May 2, 2018

10.18*

The Clorox Company Executive Incentive Compensation Plan, amended and restated as of February 7, 2008.

10-Q

001-07151

10.58

May 2, 2008

10.19*

Form of Indemnification Agreement.

10-Q

001-07151

10.27

May 4, 2010

10.2

0

*

Second Amended and Restated Executive Change in Control Severance Plan, effective February 11, 2020.

8-K

001-07151

10.1

February 14, 2020

10.2

1

*

Severance Plan for Clorox Executive Committee Members, 

second 

amended and restated effective February 11, 2020.

8-K

001-07151

10.2

February 14, 2020

10.2

2

*

The Clorox Company Executive Retirement Plan, effective as of July 1, 2011.

10-Q

001-07151

10.27

May 4, 2011

10.2

3

*

Amendment No. 1 to The Clorox Company Executive Retirement Plan.

10-K

001-07151

10.22

August 16, 2016

31

Table of Contents

 

 

Incorporated by Reference

Exhibit

Number

Exhibit Description

Form

File No.

Exhibit

Filing Date

10.2

4

*

The Clorox Company 2011 Nonqualified Deferred Compensation Plan, effective as of July 1, 2011.

10-K

001-07151

10.29

August 26, 2011

10.2

5

*

Amendment No. 1 to The Clorox Company 2011 Nonqualified Deferred Compensation Plan.

10-K

001-07151

10.24

August 16, 2016

10.2

6

*

The Clorox Company Director Equity Award Policy, effective as of November 15, 2017.

10-K

001-07151

10.26

August 14, 2018

10.2

7

Credit Agreement dated as of November 15, 2019, among The Clorox Company, the lenders listed therein, JPMorgan Chase Bank, N.A., Citibank, N.A., and Wells Fargo Bank, National Association, as Administrative Agents, and JPMorgan Chase Bank, N.A., as Servicing Agent.

8-K

001-07151

10.1

November 18, 2019

10.28

Amended and Restated Joint Venture Agreement dated as of January 31, 2003, between The Glad Products Company and certain affiliates and The Procter and Gamble Company and certain affiliates.

10-K/A

001-07151

10.26

September 30, 2016

10.29

Amendment No. 1 to the Amended and Restated Joint Venture Agreement, dated as of October 15, 2010, between The Glad Products Company and certain affiliates and The Procter & Gamble Company and certain affiliates.

10-Q

001-07151

10.2

February 2, 2018

10.3

0

First Extension and Amendment of the Amended and Restated Joint Venture Agreement, dated as of December 20, 2017, between The Glad Products Company and certain affiliates and The Procter & Gamble Company and certain affiliates.

10-Q

001-07151

10.1

February 2, 2018

21

Subsidiaries.

23

Consent of Independent Registered Public Accounting Firm.

31.1

Certification of the Chief Executive Officer of The Clorox Company pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of the Chief Financial Officer of The Clorox Company pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32

Certification of the Chief Executive Officer and Chief Financial Officer of The Clorox Company pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

99.1

Management’s Discussion and Analysis of Financial Condition and Results of Operations, Consolidated Financial Statements, Management’s Report on Internal Control over Financial Reporting and Reports of Independent Registered Public Accounting Firm.

 

 

 

 

99.2

Reconciliation of Economic Profit (Unaudited).

101.INS

XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH

XBRL Taxonomy Extension Schema Document.

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB

XBRL Taxonomy Extension Label Linkbase Document.

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).

____________________

(*) Indicates a management or director contract or compensatory plan or arrangement required to be filed as an exhibit to this report.

32

Table of Contents

 

 

ITEM 16. FORM 10-K SUMMARY

None.

33

Table of Contents

 

 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

THE CLOROX COMPANY

 

Date: August 13, 2020

By:  

/s/ Benno Dorer

Benno Dorer

 

Chair and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature

     

Title

     

Date

/s/ A. Banse

Director

August 13, 2020

A. Banse

/s/ R. H. Carmona

Director

August 13, 2020

R. H. Carmona

/s/ S. C. Fleischer

Director

August 13, 2020

S. C. Fleischer

/s/ E. Lee

Director

August 13, 2020

E. Lee

/s/ A. D. D. Mackay

Director

August 13, 2020

A. D. D. Mackay

/s/ R. W. Matschullat

Director

August 13, 2020

R. W. Matschullat

/s/ M. J. Shattock

Director

August 13, 2020

M. J. Shattock

/s/ K. Tesija 

Director

August 13, 2020

K. Tesija

/s/ P. Thomas-Graham

Director

August 13, 2020

P. Thomas-Graham

/s/ R. J. Weiner

Director

August 13, 2020

R. J. Weiner

/s/ C. J. Williams

Director

August 13, 2020

C. J. Williams

/s/ B. Dorer

Chair and Chief Executive Officer

(Principal Executive Officer)

August 13, 2020

B. Dorer

/s/ K. B. Jacobsen

Executive Vice President – Chief Financial Officer

(Principal Financial Officer)

August 13, 2020

K. B. Jacobsen

/s/ J. R. Baker

Vice President – Chief Accounting Officer and Corporate Controller (Principal Accounting Officer)

August 13, 2020

J. R. Baker

34


